Alaunos Therapeutics, Inc. (TCRT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 1M 2M 3M Q3 '21: 398K Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 2.9M Q4 '22: 11K Q1 '23: 0 Q2 '23: 4K Q3 '23: 0 Q4 '23: 1K Q1 '24: 1K Q2 '24: 4K Q3 '24: 0 Q4 '24: 4K Q1 '25: 2K Q2 '25: 0 Q3 '25: 0 Q4 '25: 3K Q1 '26: 0 Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '21: -22.3M Q4 '21: -11.1M Q1 '22: -9.1M Q2 '22: -9.2M Q3 '22: -8.3M Q4 '22: -8.5M Q1 '23: -9.7M Q2 '23: -8M Q3 '23: -8.7M Q4 '23: -7.9M Q1 '24: -1.7M Q2 '24: -1.2M Q3 '24: -1.1M Q4 '24: -755K Q1 '25: -1.1M Q2 '25: -1M Q3 '25: -1.2M Q4 '25: -907K Q1 '26: -1M Q2 '26: -952K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '21: -22.7M Q4 '21: -11.8M Q1 '22: -9.8M Q2 '22: -9.9M Q3 '22: -8.9M Q4 '22: -9.2M Q1 '23: -10M Q2 '23: -8.8M Q3 '23: -8.5M Q4 '23: 22.6M Q1 '24: -1.7M Q2 '24: -1.1M Q3 '24: -1.1M Q4 '24: -742K Q1 '25: -1.1M Q2 '25: -1.1M Q3 '25: -1.2M Q4 '25: -893K Q1 '26: -1M Q2 '26: -952K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '21: -9.6M Q4 '21: -15.1M Q1 '22: -7.8M Q2 '22: -8.2M Q3 '22: -6.1M Q4 '22: -7.1M Q1 '23: -9.4M Q2 '23: -7M Q3 '23: -6.4M Q4 '23: -7.4M Q1 '24: -1.9M Q2 '24: -1.7M Q3 '24: -781K Q4 '24: -592K Q1 '25: -772K Q2 '25: -701K Q3 '25: -844K Q4 '25: -552K Q1 '26: -1M Q2 '26: -300K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q2 '20: -17.5M Q3 '20: -18.1M Q4 '20: -20.8M Q1 '21: -16M Q2 '21: -23.3M Q3 '21: -9.9M Q4 '21: -15.5M Q1 '22: -7.8M Q2 '22: -8.2M Q3 '22: -6.2M Q4 '22: -7.2M Q1 '23: -9.4M Q2 '23: -7.1M Q3 '23: -6.4M Q4 '23: -7.4M Q1 '24: -1.9M Q2 '24: -1.7M Q3 '24: -781K Q4 '24: -592K Q4 '25: -553K Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q2 '11: 67.2M Q3 '11: 68.1M Q2 '12: 78.5M Q3 '12: 78.7M Q2 '21: 214.4M Q3 '21: 214.5M Q1 '22: 214.9M Q2 '22: 215M Q3 '22: 215.1M Q1 '23: 16M Q2 '23: 1.6M Q3 '23: 1.6M Q1 '24: 1.6M Q2 '24: 1.6M Q3 '24: 1.6M Q1 '25: 1.6M Q2 '25: 1.7M Q3 '25: 2.2M Q1 '26: 1.9M Q2 '26: 2.4M Q3 '11 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q3 '21: -0.43 Q4 '21: -0.38 Q1 '22: -0.33 Q2 '22: -0.27 Q3 '22: -0.20 Q4 '22: -2.62 Q1 '23: -3.20 Q2 '23: -8.64 Q3 '23: -13.90 Q4 '23: -16.32 Q1 '24: -16.74 Q2 '24: -11.96 Q3 '24: -7.36 Q4 '24: -2.92 Q1 '25: -2.54 Q2 '25: -2.46 Q3 '25: -2.31 Q4 '25: -2.21 Q1 '26: -2.13 Q2 '26: -1.91 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.